Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) has secured up to $10 million in debt financing that strengthens the company’s balance sheet and could help with future acquisitions or licensing deals.
The debt funding comes from Hercules Technology Growth Capital (Nasdaq:HTGC), a financial firm that provides loans to technology companies, according to a statement from Dublin, Ohio-based Navidea. Navidea had been branded as Neoprobe, but formally switched to its previously announced new name and new ticker symbol today.
The initial portion of the funding, $7 million, closed in late December and bears interest at a prime-based variable rate, currently at 10 percent. Up to $3 million of that amount is convertible to Navidea stock at a price of $2.77 per share. Navidea shares closed at $2.76 yesterday.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The second portion of the funding, $3 million, would become available to Navidea upon U.S. regulatory approval of its drug candidate Lymphoseek, which could happen this summer. Lymphoseek is a targeting agent used by surgeons to identify lymph nodes in patients with breast cancer or melanoma and to indicate whether cancer has spread to a particular lymph node.
Last month, Navidea licensed from AstraZeneca (NYSE:AZN) the worldwide rights to an imaging drug candidate that could aid in the diagnosis of Alzheimer’s disease.
The company also has a third drug in development called RIGScan, which is a radiopharmaceutical targeting agent used to detect tumors left behind after colon cancer surgery. It’s several years from commercialization.
